Literature DB >> 21534935

Optimizing clozapine treatment.

J Nielsen1, P Damkier, H Lublin, D Taylor.   

Abstract

OBJECTIVE: Clozapine treatment remains the gold standard for treatment-resistant schizophrenia, but treatment with clozapine is associated with several side-effects that complicate the use of the drug. This clinical overview aims to provide psychiatrists with knowledge about how to optimize clozapine treatment. Relevant strategies for reducing side-effects and increasing the likelihood of response are discussed.
METHOD: Studies of clozapine available in MEDLINE were reviewed.
RESULTS: A slow up-titration of clozapine is recommended in order to reach the optimal dosage of clozapine and diminish the risk of dose-dependent side-effects. Particularly, in case of partial response or non-response, the use of therapeutic drug monitoring of clozapine is recommended. Plasma levels above the therapeutic threshold of 350-420 ng/ml are necessary to determine non-response to clozapine. To ease the burden of dose-dependent side-effects, dose reduction of clozapine should be tried and combination with another antipsychotic drug may facilitate further dose reduction. For most side-effects, counteracting medication exists. Augmentation with lamotrigine, antipsychotics, or electroconvulsive therapy may be beneficial in case of partial response to clozapine.
CONCLUSION: Treatment with clozapine should be optimized in order to increase the rate of response and to minimize side-effects, thus diminishing the risk of discontinuation and psychotic relapse.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21534935     DOI: 10.1111/j.1600-0447.2011.01710.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  26 in total

1.  Managing pathologic aggression in people with psychotic disorders.

Authors:  Dominique Bourget; Alain Labelle
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

2.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 3.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

4.  Sialorrhea and aspiration pneumonia: a case study.

Authors:  Eileen Trigoboff; Jeffery Grace; Herman Szymanski; Jaspinder Bhullar; Claudia Lee; Thomas Watson
Journal:  Innov Clin Neurosci       Date:  2013-05

Review 5.  The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.

Authors:  Christoffer Polcwiartek; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-12-02       Impact factor: 4.530

6.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

7.  Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.

Authors:  Samantha A Hollingworth; Karl Winckel; Nargess Saiepour; Amanda J Wheeler; Nicholas Myles; Dan Siskind
Journal:  Psychopharmacology (Berl)       Date:  2018-03-27       Impact factor: 4.530

Review 8.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

9.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

Review 10.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.